

BETTER EDUCATION ON GLOMERULONEPHRITIS: IMPROVING KNOWLEDGE OF IgA NEPHROPATHY



Clinical Resources

ClinicalTrials.gov (<https://www.clinicaltrials.gov>)

- NCT04573478. Atrasentan in patients with IgA nephropathy (ALIGN).
- NCT04573920. Atrasentan in patients with proteinuric glomerular diseases (AFFINITY).
- NCT04578834. Study of efficacy and safety of LNP023 in primary IgA nephropathy patients (APPLAUSE-IgAN).
- NCT03608033. Study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IgA) nephropathy.
- NCT03608033. Study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IgA) nephropathy.
- NCT04564339. Study of ravulizumab in proliferative lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN).
- NCT04291781. A study of RC18 administered subcutaneously to subjects with IgA (immunoglobulin A) nephropathy.
- NCT03945318. Safety and tolerability of BION-1301 in healthy volunteers and adults with IgA nephropathy (IgAN).
- NCT01738035. The effect of Nefecon® in patients with primary IgA nephropathy at risk of developing end-stage renal disease (NEFIGAN).
- NCT03643965. Efficacy and safety of Nefecon in patients with primary IgA (immunoglobulin A) nephropathy (Nefigard).
- NCT03453619. Phase II study assessing safety and efficacy of APL-2 in glomerulopathies.
- NCT04014335. A study to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B, in adult participants with Primary IgA nephropathy.
- NCT03841448. A study of cemdisiran in adults with immunoglobulin A nephropathy (IgAN)
- NCT04684745. Safety and tolerability of BION-1301 in healthy volunteers and adults with IgA nephropathy (IgAN).
- NCT04287985. Safety and efficacy study of VIS649 for IgA nephropathy.

Guidelines

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021

Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [published correction appears in *Am J Kidney Dis.* 2017 Mar;69(3):485]. *Am J Kidney Dis.* 2013;62(3):403-441. doi:10.1053/j.ajkd.2013.06.002

BETTER EDUCATION ON GLOMERULONEPHRITIS: IMPROVING KNOWLEDGE OF IgA NEPHROPATHY



Clinical Trials and Other Articles

1. Rajasekaran A et al. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. *Am J Med Sci.* 2021;361(2):176-194. doi:10.1016/j.amjms.2020.10.003
2. Lai KN et al. IgA nephropathy. *Nat Rev Dis Primers.* 2016;2:16001. doi:10.1038/nrdp.2016.1
3. McQuarrie EP et al. The incidence of biopsy-proven IgA nephropathy is associated with multiple socioeconomic deprivation. *Kidney Int.* 2014;85(1):198-203. doi:10.1038/ki.2013.329
4. Libório AB et al. Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function. *PLoS One.* 2012;7(5):e37763. doi:10.1371/journal.pone.0037763
5. Carter SA et al. Identifying Outcomes important to patients with glomerular disease and their caregivers. *Clin J Am Soc Nephrol.* 2020;15(5):673-684. doi:10.2215/CJN.13101019
6. Kraus MA et al. Intensive hemodialysis and health-related quality of life. *Am J Kidney Dis.* 2016;68(5S1):S33-S42. doi:10.1053/j.ajkd.2016.05.023
7. Mizerska-Wasiak M et al. Health-related quality of life in children with immunoglobulin A nephropathy- results of a multicentre national study. *Arch Med Sci.* 2020;17(1):84-91. doi:10.5114/aoms.2020.100367.
8. Thompson A et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. *Clin J Am Soc Nephrol.* 2019;14(3):469-481. doi:10.2215/CJN.08600718
9. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
10. Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. *Br J Clin Pharmacol.* 2013;76(4):516-523. doi:10.1111/bcp.12104.
11. Canney M, et al. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy. *J Am Soc Nephrol.* 2021;32(2):436-447. doi:10.1681/ASN.2020030349
12. Barratt et al. Nefecon for the treatment of IgA nephropathy in patients at risk of progressing to end-stage renal disease: The NEFIGARD phase 3 trial results. *Kidney Int Rep.* 2021;6(4):361. <https://doi.org/10.1016/j.ekir.2021.03.868>.

Patient Resources

Medline Plus: <https://medlineplus.gov/ency/article/000466.htm>

Merck Manual: <https://www.merckmanuals.com/professional/genitourinary-disorders/glomerular-disorders/immunoglobulin-a-nephropathy>

IgA Nephropathy Association: <https://igan.org/>

National Kidney Foundation: <https://www.kidney.org/search-results?solr-keywords=iga%20nephropathy>

National Institute of Diabetes and Digestive and Kidney Diseases: <https://www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy>